5-Fluorouracil
Information
- Drug Name
- 5-Fluorouracil
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| The marked synergy noted with pyrimidine-based ant... | ROS1 | ROS1 OVEREXPRESSION | Sensitivity | true | MMMP | detail |
| ABCB8 mediates the resistance to doxorubicin (but ... | ABCB8 | ABCB8 UNDEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| Accordingly, ABCB5 is defined as melanoma chemores... | ABCB5 | ABCB5 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| Forced expression of transcription factor E2F1 via... | E2F1 | E2F1 OVEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| Effect of focal adhesion kinase (FAK) downregulati... | PTK2 | PTK2 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| Specific c-Myc inhibition increased melanoma susce... | MYC | MYC UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| c-Myc is able to sensitize human melanoma cells to... | MYC | MYC OVEREXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03279237 | Active, not recruiting | Phase 1 | A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers | October 24, 2017 | September 2023 |
| NCT04375605 | Active, not recruiting | Phase 3 | Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ | June 3, 2020 | December 2025 |
| NCT03785873 | Active, not recruiting | Phase 1/Phase 2 | Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer | May 22, 2019 | May 2025 |
| NCT03387085 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | March 16, 2018 | October 2023 |
| NCT03358472 | Active, not recruiting | Phase 3 | Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | December 1, 2017 | December 27, 2024 |
| NCT03563157 | Active, not recruiting | Phase 1/Phase 2 | QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine | May 25, 2018 | December 30, 2022 |
| NCT04390399 | Active, not recruiting | Phase 2 | Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | July 21, 2020 | September 30, 2024 |
| NCT05253846 | Active, not recruiting | Phase 2 | Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 | January 25, 2022 | October 30, 2028 |
| NCT03221426 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | October 9, 2017 | June 27, 2025 |
| NCT03493048 | Active, not recruiting | Phase 2 | Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM | April 15, 2018 | June 2025 |
| NCT03206151 | Active, not recruiting | Phase 3 | CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer | December 12, 2017 | June 30, 2024 |
| NCT04882241 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension | July 29, 2020 | June 27, 2025 |
| NCT03306901 | Active, not recruiting | N/A | Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma | October 20, 2017 | December 31, 2033 |
| NCT02578368 | Active, not recruiting | Phase 3 | Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | February 2016 | February 2026 |
| NCT02509286 | Active, not recruiting | Phase 3 | Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus | January 2016 | December 31, 2024 |
| NCT03675737 | Active, not recruiting | Phase 3 | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) | November 8, 2018 | March 1, 2025 |
| NCT02138617 | Active, not recruiting | Phase 2 | Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer | May 2014 | June 1, 2027 |
| NCT01358877 | Active, not recruiting | Phase 3 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | November 8, 2011 | November 28, 2024 |
| NCT03904381 | Active, not recruiting | Phase 4 | Efficacy and Safety of XEN® Gel Stent and Post-operative Management in Patients With Open Angle Glaucoma | January 1, 2016 | January 1, 2025 |
| NCT00176774 | Completed | Phase 2 | Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma | February 2001 | April 2004 |
| NCT00193011 | Completed | Phase 3 | Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer | March 2002 | August 2004 |
| NCT00193141 | Completed | Phase 2 | Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer | October 1999 | July 2007 |
| NCT00193219 | Completed | Phase 2 | Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer | July 2005 | July 2010 |
| NCT00193882 | Completed | Phase 3 | Advanced Oesophageal Cancer Study to Compare Quality of Life and Palliation of Dysphagia. | July 7, 2003 | June 18, 2013 |
| NCT00199797 | Completed | Phase 1 | Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer | April 18, 2005 | April 1, 2016 |
| NCT00209716 | Completed | Phase 1/Phase 2 | Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer. | December 2003 | November 2009 |
| NCT00230451 | Completed | Phase 2 | Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma | November 1997 | July 2008 |
| NCT00246103 | Completed | Phase 1 | Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies | March 2004 | April 2008 |
| NCT00251355 | Completed | Phase 1 | Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer | January 1998 | August 2008 |
| NCT00278889 | Completed | Phase 2 | Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) | January 2006 | October 2009 |
| NCT00280761 | Completed | Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy | December 2003 | September 19, 2021 | |
| NCT00305188 | Completed | Phase 3 | Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. | December 2005 | October 2009 |
| NCT00307736 | Completed | Phase 1/Phase 2 | Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer | May 2006 | July 2011 |
| NCT00308516 | Completed | Phase 2 | 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer | March 2006 | February 2012 |
| NCT00331097 | Completed | Phase 3 | ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment | July 2003 | November 2014 |
| NCT00336791 | Completed | Phase 3 | Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer | September 2003 | September 2010 |
| NCT00346489 | Completed | Phase 4 | Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin C | September 2004 | August 2007 |
| NCT00354978 | Completed | Phase 2 | Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients | January 2005 | March 2011 |
| NCT00378716 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Resected Colon Cancer | February 1997 | April 2009 |
| NCT00402545 | Completed | Phase 1 | C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck | January 2007 | July 2009 |
| NCT00417209 | Completed | Phase 3 | Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen | December 2006 | November 2009 |
| NCT00418938 | Completed | Phase 2 | SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial | November 1, 2006 | April 1, 2013 |
| NCT00425516 | Completed | Phase 2 | Breast Cancer Treated by Neoadjuvant Chemotherapy | January 2007 | August 2014 |
| NCT00469443 | Completed | Phase 3 | Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC | December 2006 | February 2010 |
| NCT00499850 | Completed | Phase 1 | Phase I FOLFOX Combination | August 2005 | April 2008 |
| NCT00507091 | Completed | Phase 1 | Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination | August 2005 | June 2008 |
| NCT00510367 | Completed | Early Phase 1 | Primary Breast Cancer Occurring Concomitant With Pregnancy | August 7, 2001 | July 8, 2020 |
| NCT00513383 | Completed | Phase 1 | Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck | April 2006 | October 2012 |
| NCT00515216 | Completed | Phase 2 | Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors | August 2007 | November 2013 |
| NCT00525785 | Completed | Phase 2 | Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ) | January 2004 | January 2016 |
| NCT00525915 | Completed | Phase 2 | Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma | April 2005 | March 2013 |
| NCT00526110 | Completed | Phase 1/Phase 2 | Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients | August 2004 | June 2015 |
| NCT00527111 | Completed | Phase 2 | Pre-op Rectal ChemoRad +/- Cetuximab | February 2007 | January 2015 |
| NCT00548548 | Completed | Phase 3 | A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer | September 2007 | November 2013 |
| NCT00555672 | Completed | Phase 1 | Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer | August 2008 | August 2010 |
| NCT00559845 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer | February 2008 | July 2015 |
| NCT00565448 | Completed | Phase 2 | Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents | November 2007 | January 2012 |
| NCT00580983 | Completed | N/A | Optimized Intensity Modulated Irradiation for Head and Neck Cancer | August 2003 | June 2010 |
| NCT00000122 | Completed | Phase 3 | Fluorouracil Filtering Surgery Study (FFSS) | September 1985 | June 1988 |
| NCT00001428 | Completed | Phase 2 | A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer | February 1995 | December 2000 |
| NCT00001498 | Completed | Phase 2 | A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer | February 1996 | December 2000 |
| NCT00001579 | Completed | Phase 1 | A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors | June 1997 | March 2001 |
| NCT00002774 | Completed | Phase 2 | Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer | June 1996 | June 2005 |
| NCT00009737 | Completed | Phase 3 | A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer | November 1998 | April 2004 |
| NCT00054873 | Completed | Phase 2 | Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer | November 2003 | December 2004 |
| NCT00054977 | Completed | Phase 1 | Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors | February 2003 | September 2006 |
| NCT00059826 | Completed | Phase 2 | Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer | March 2003 | February 2011 |
| NCT00061815 | Completed | Phase 3 | Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer | March 2003 | November 2005 |
| NCT00111761 | Completed | Phase 2 | Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer | July 2002 | October 2008 |
| NCT00121992 | Completed | Phase 3 | Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment | July 1999 | March 6, 2013 |
| NCT00123318 | Completed | Phase 3 | A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer | February 2003 | February 2012 |
| NCT00124111 | Completed | Phase 2 | A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer | ||
| NCT00126256 | Completed | Phase 3 | Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer | February 2002 | February 2006 |
| NCT00139230 | Completed | Phase 2 | Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck | January 1997 | December 2006 |
| NCT00139243 | Completed | Phase 1/Phase 2 | Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck | October 1997 | January 2006 |
| NCT00139269 | Completed | Phase 1/Phase 2 | Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck | February 1998 | December 2006 |
| NCT00165191 | Completed | Phase 2 | Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus | August 1998 | January 2006 |
| NCT00688740 | Completed | Phase 3 | Docetaxel in Node Positive Adjuvant Breast Cancer | June 1997 | January 2010 |
| NCT00689624 | Completed | Phase 2 | Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer | July 2007 | December 2010 |
| NCT00737373 | Completed | Phase 2 | Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer | August 2007 | March 2011 |
| NCT00786643 | Completed | Phase 2 | Study of Gamma Interfereon in Metastatic Colorectal Carcinoma | February 2006 | March 2010 |
| NCT00811447 | Completed | Phase 3 | Taxotere New Indication - Gastric Cancer Treatment Registration Trial | November 2008 | June 2012 |
| NCT00847912 | Completed | Phase 4 | CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial | June 26, 2009 | July 30, 2016 |
| NCT00849615 | Completed | Phase 2 | Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | February 2009 | January 2016 |
| NCT00865189 | Completed | Phase 2 | A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer | October 23, 2007 | March 23, 2016 |
| NCT00932438 | Completed | Phase 1/Phase 2 | Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab | June 2009 | December 2012 |
| NCT00941655 | Completed | Phase 3 | Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial | July 22, 2009 | June 18, 2012 |
| NCT00950300 | Completed | Phase 3 | A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer | October 16, 2009 | January 24, 2017 |
| NCT00971932 | Completed | Phase 2 | Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | July 2009 | |
| NCT00981656 | Completed | Phase 2 | Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer | November 2009 | August 15, 2023 |
| NCT00995293 | Completed | Phase 3 | Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial | August 27, 2009 | January 26, 2018 |
| NCT01036087 | Completed | Phase 2 | Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer | November 2010 | August 9, 2022 |
| NCT01081041 | Completed | Phase 2 | A Study in Head and Neck Cancer | June 2010 | September 2015 |
| NCT01121848 | Completed | Phase 3 | Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer | July 2010 | October 2013 |
| NCT01177956 | Completed | Phase 3 | A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck | December 2009 | November 2012 |
| NCT01183663 | Completed | Phase 1 | Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | August 2010 | May 2016 |
| NCT01183780 | Completed | Phase 3 | A Study in Second Line Metastatic Colorectal Cancer | December 2, 2010 | June 20, 2016 |
| NCT01206530 | Completed | Phase 1/Phase 2 | FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer | September 2010 | September 2017 |
| NCT01216644 | Completed | Phase 2/Phase 3 | 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer | August 2010 | May 2019 |
| NCT01226719 | Completed | Phase 2 | FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only | December 2010 | March 2014 |
| NCT01227707 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer. | November 2005 | August 2010 |
| NCT01246960 | Completed | Phase 2 | A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer | April 2011 | May 2014 |
| NCT01374425 | Completed | Phase 2 | Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) | August 2011 | July 2015 |
| NCT01399684 | Completed | Phase 2 | A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer | November 2011 | February 2014 |
| NCT01481545 | Completed | Phase 2 | Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer | December 2006 | December 2016 |
| NCT01490866 | Completed | Phase 2 | A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) | January 2012 | July 2015 |
| NCT01498783 | Completed | Phase 1 | Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma | December 2011 | May 2014 |
| NCT01523431 | Completed | Phase 2/Phase 3 | Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients | March 8, 2012 | April 27, 2016 |
| NCT01590719 | Completed | Phase 2 | A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer | July 2012 | October 2014 |
| NCT01593020 | Completed | Phase 2 | Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 | August 3, 2012 | November 4, 2020 |
| NCT01634555 | Completed | Phase 2 | A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI | October 2012 | February 2018 |
| NCT01650428 | Completed | Phase 2 | Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery | April 2013 | February 14, 2019 |
| NCT01652482 | Completed | Phase 2 | Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) | October 2012 | November 2014 |
| NCT01718873 | Completed | Phase 3 | Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer | May 2012 | December 2019 |
| NCT01726452 | Completed | Phase 3 | NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) | January 24, 2013 | August 4, 2022 |
| NCT01750918 | Completed | Phase 1/Phase 2 | BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) | December 19, 2012 | June 18, 2020 |
| NCT01774786 | Completed | Phase 3 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer | June 10, 2013 | December 31, 2019 |
| NCT01821612 | Completed | Early Phase 1 | Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer | May 2013 | June 15, 2018 |
| NCT01836029 | Completed | Phase 2 | Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | October 14, 2013 | September 19, 2016 |
| NCT01855828 | Completed | Phase 2 | Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | September 2013 | August 2018 |
| NCT01884259 | Completed | Phase 2 | Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN | May 2013 | January 13, 2022 |
| NCT01896531 | Completed | Phase 2 | A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer | August 14, 2013 | January 26, 2021 |
| NCT01913639 | Completed | Phase 2 | FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer | July 2013 | June 2019 |
| NCT01930552 | Completed | Phase 1 | A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies | September 2013 | December 2014 |
| NCT01959139 | Completed | Phase 1/Phase 2 | S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer | January 23, 2014 | November 9, 2023 |
| NCT01966471 | Completed | Phase 3 | A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | January 31, 2014 | June 4, 2021 |
| NCT02114359 | Completed | Phase 3 | Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer | February 2014 | February 2020 |
| NCT02115204 | Completed | Phase 3 | 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF | June 2000 | August 2010 |
| NCT02129257 | Completed | Phase 2 | Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer | May 26, 2014 | September 25, 2017 |
| NCT02132949 | Completed | Phase 2 | A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer | July 14, 2014 | August 25, 2020 |
| NCT02155439 | Completed | Phase 4 | Treatment of Keloidscars With Intralesional Triamcinolone and 5-fluorouracil Injections-prospective, Randomized, Controlled Trial - Pilot Study | May 2014 | January 2018 |
| NCT02172976 | Completed | Phase 2/Phase 3 | Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma | November 2014 | May 2020 |
| NCT02246049 | Completed | Phase 2 | A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC | May 2014 | February 2017 |
| NCT02362152 | Completed | The Real Life Topical Field Treatment of Actinic Keratosis Study | July 2014 | December 2015 | |
| NCT02383966 | Completed | Phase 3 | Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer | July 31, 2015 | December 20, 2021 |
| NCT02450058 | Completed | Phase 3 | Adjuvant FEC Versus EP in Breast Cancer (MIG5) | November 1996 | May 2012 |
| NCT02545504 | Completed | Phase 3 | Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | October 13, 2015 | May 15, 2019 |
| NCT02563054 | Completed | Phase 3 | A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer | April 2003 | August 2010 |
| NCT02582970 | Completed | Phase 4 | A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum | May 2005 | April 2008 |
| NCT02620423 | Completed | Phase 1 | Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | December 2015 | August 2018 |
| NCT02625610 | Completed | Phase 3 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | December 24, 2015 | June 3, 2021 |
| NCT02661971 | Completed | Phase 2/Phase 3 | FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) | June 2016 | June 20, 2022 |
| NCT02705352 | Completed | Phase 2 | 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts | August 25, 2016 | January 25, 2019 |
| NCT02767219 | Completed | Phase 3 | The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery | May 2016 | May 2019 |
| NCT02846428 | Completed | Phase 2 | To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer | March 2004 | December 2011 |
| NCT02928224 | Completed | Phase 3 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | October 13, 2016 | November 10, 2022 |
| NCT02954536 | Completed | Phase 2 | Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer | November 3, 2016 | March 14, 2023 |
| NCT03085914 | Completed | Phase 1/Phase 2 | A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) | May 2, 2017 | July 13, 2020 |
| NCT03231722 | Completed | Phase 3 | First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS | September 13, 2017 | June 24, 2022 |
| NCT03314935 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | November 21, 2017 | November 28, 2022 |
| NCT03365765 | Completed | Phase 3 | mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer | February 12, 2018 | December 31, 2022 |
| NCT03446872 | Completed | Post Marketing Surveillance Study for ONIVYDE® in South Korea | March 8, 2018 | August 29, 2020 | |
| NCT03721653 | Completed | Phase 2 | FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients | November 30, 2018 | August 31, 2023 |
| NCT03778593 | Completed | Phase 2 | FOLFIRINOX for 2nd-line Treatment of BTC | March 1, 2019 | January 14, 2021 |
| NCT04031703 | Completed | Phase 3 | Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN) | January 1, 2011 | April 20, 2016 |
| NCT04127019 | Completed | Phase 3 | Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER) | June 1, 2010 | June 15, 2017 |
| NCT04547153 | Completed | Phase 2 | Infusional Fluorouracil and Weekly Docetaxel for Gastric Cancer With Bone Marrow Involvement and DIC | January 15, 2021 | March 22, 2024 |
| NCT04812626 | Completed | N/A | Intralesional Triamcinolone Acetonide and Its Combination With 5-fluorouracil in Keloids and Hypertrophic Scars | January 28, 2021 | September 14, 2021 |
| NCT06175676 | Completed | Phase 1 | Safety and Efficacy of Thermosensitive Hydroxybutyl Chitosan and 5-fluorouracil Assisted Endoscopic Dacryocystorhinostomy in the Treatment of Chronic Dacryocystitis | December 3, 2021 | December 3, 2023 |
| NCT06259058 | Not yet recruiting | Phase 1/Phase 2 | Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer | April 1, 2024 | December 1, 2027 |
| NCT04890522 | Not yet recruiting | Phase 2/Phase 3 | An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC | July 1, 2021 | December 31, 2028 |
| NCT06197438 | Not yet recruiting | Phase 2 | Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer | January 1, 2024 | April 1, 2025 |
| NCT05640726 | Not yet recruiting | Phase 2 | The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy | May 1, 2023 | May 1, 2026 |
| NCT05314998 | Not yet recruiting | Phase 3 | Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature | June 15, 2024 | September 1, 2031 |
| NCT06383078 | Not yet recruiting | Phase 2 | HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer | April 20, 2024 | December 30, 2027 |
| NCT06057038 | Recruiting | Phase 1 | A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors | November 24, 2023 | October 7, 2027 |
| NCT04847063 | Recruiting | Phase 1 | Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies | October 19, 2021 | December 30, 2031 |
| NCT06332079 | Recruiting | Phase 2 | Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients | March 13, 2024 | February 2027 |
| NCT03370406 | Recruiting | Phase 1 | Intralesional 5-Fluorouracil (5FU), Topical Imiquimod Treatment for SCC | August 3, 2018 | September 30, 2024 |
| NCT03764553 | Recruiting | Phase 2 | Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer | May 1, 2019 | August 1, 2024 |
| NCT03421288 | Recruiting | Phase 2 | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness | September 14, 2018 | December 31, 2027 |
| NCT06150144 | Recruiting | Phase 3 | The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma | May 25, 2023 | May 25, 2025 |
| NCT05125055 | Recruiting | Phase 2/Phase 3 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | October 1, 2021 | December 30, 2026 |
| NCT03715933 | Recruiting | Phase 1 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | October 10, 2018 | July 2026 |
| NCT05383352 | Recruiting | Phase 1 | A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas | May 30, 2022 | September 30, 2024 |
| NCT05412082 | Recruiting | Phase 1 | SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer | October 5, 2022 | October 2027 |
| NCT05239741 | Recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) | April 2, 2022 | November 10, 2026 |
| NCT05480280 | Recruiting | Phase 2 | mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer | July 20, 2022 | December 2023 |
| NCT05489211 | Recruiting | Phase 2 | Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | September 6, 2022 | August 19, 2026 |
| NCT05491512 | Recruiting | Phase 2 | A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer | August 4, 2022 | August 4, 2025 |
| NCT04595929 | Recruiting | N/A | Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt- | February 10, 2020 | January 10, 2029 |
| NCT05609370 | Recruiting | Phase 1/Phase 2 | A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer | January 29, 2023 | April 2028 |
| NCT05610163 | Recruiting | Phase 2 | Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation | December 8, 2022 | September 2032 |
| NCT06328738 | Recruiting | Phase 1 | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | June 1, 2024 | July 2028 |
| NCT04502641 | Recruiting | Phase 3 | Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial | August 1, 2020 | August 1, 2025 |
| NCT05702229 | Recruiting | Phase 2 | Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | January 16, 2023 | March 31, 2026 |
| NCT04447352 | Recruiting | Phase 3 | HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) | December 17, 2020 | May 1, 2027 |
| NCT05838391 | Recruiting | N/A | Adaptive Radiation in Anal Cancer | May 18, 2023 | December 31, 2028 |
| NCT04420884 | Recruiting | Phase 1/Phase 2 | A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | July 22, 2020 | January 15, 2026 |
| NCT05862168 | Recruiting | Phase 2 | Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial | May 8, 2023 | June 30, 2028 |
| NCT05067283 | Recruiting | Phase 1 | A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | December 17, 2021 | August 19, 2026 |
| NCT01628211 | Recruiting | Phase 2 | Second Look Laparoscopy in Colorectal Cancer | April 2012 | December 2024 |
| NCT04371224 | Recruiting | Phase 2 | NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer | June 23, 2020 | December 31, 2025 |
| NCT04361708 | Recruiting | Phase 1 | Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies | May 8, 2020 | May 2027 |
| NCT04358354 | Recruiting | Phase 3 | Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer | October 22, 2020 | December 31, 2024 |
| NCT05286814 | Recruiting | Phase 2 | M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma | October 24, 2022 | December 31, 2028 |
| NCT04310176 | Recruiting | Phase 2 | Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer | May 24, 2019 | November 2024 |
| NCT02087475 | Recruiting | Phase 3 | Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin | January 2011 | December 2024 |
| NCT05960955 | Recruiting | Phase 2 | Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | November 13, 2023 | November 30, 2027 |
| NCT05062317 | Recruiting | Phase 2 | ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases | April 26, 2022 | February 28, 2026 |
| NCT03944915 | Recruiting | Phase 2 | De-Escalation Therapy for Human Papillomavirus Negative Disease | August 26, 2019 | July 1, 2024 |
| NCT06219941 | Recruiting | Phase 2 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | December 13, 2023 | January 19, 2027 |
| NCT06019130 | Recruiting | Phase 2 | Nivolumab in Children and Adults With Nasopharyngeal Carcinoma | January 10, 2023 | January 9, 2028 |
| NCT05007106 | Recruiting | Phase 2 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | September 16, 2021 | February 22, 2027 |
| NCT05319639 | Recruiting | Phase 1/Phase 2 | Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab | February 16, 2023 | December 31, 2024 |
| NCT05382442 | Recruiting | Phase 2 | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | July 27, 2022 | December 25, 2026 |
| NCT05152147 | Recruiting | Phase 3 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | December 2, 2021 | February 1, 2026 |
| NCT04675983 | Terminated | Phase 3 | A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106) | March 10, 2021 | February 12, 2023 |
| NCT00570531 | Terminated | Phase 2 | Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma | June 2007 | June 2013 |
| NCT00037180 | Terminated | Phase 2 | For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy | April 2002 | January 2003 |
| NCT02465593 | Terminated | Phase 1/Phase 2 | A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer | June 2015 | July 28, 2021 |
| NCT00563862 | Terminated | N/A | Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0) | July 1999 | June 2007 |
| NCT03136406 | Terminated | Phase 1/Phase 2 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | August 11, 2017 | November 1, 2019 |
| NCT00551759 | Terminated | Phase 2 | Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer | October 2, 2008 | February 2014 |
| NCT00539617 | Terminated | Phase 2 | Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery | October 5, 2007 | May 12, 2011 |
| NCT00508872 | Terminated | Phase 2 | Folfox-B Study for Patients With Colorectal Liver Metastases | November 2005 | June 2009 |
| NCT03294252 | Terminated | Phase 1/Phase 2 | Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers | May 24, 2017 | October 1, 2021 |
| NCT00599131 | Terminated | Phase 2 | Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE) | August 2007 | October 2010 |
| NCT00602745 | Terminated | Phase 3 | S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen | February 2008 | March 2010 |
| NCT00611858 | Terminated | Phase 2 | Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer | May 2008 | September 2016 |
| NCT00625898 | Terminated | Phase 3 | BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab | April 2008 | July 2014 |
| NCT00400205 | Terminated | Phase 2 | Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil | August 2006 | September 2009 |
| NCT00755118 | Terminated | Phase 2 | Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc | October 2008 | August 2012 |
| NCT00782041 | Terminated | Phase 2 | Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer | January 2003 | |
| NCT00889343 | Terminated | Phase 2 | Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer | March 2009 | December 2012 |
| NCT03515941 | Terminated | Early Phase 1 | Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers | June 22, 2018 | June 18, 2020 |
| NCT00307723 | Terminated | Phase 1/Phase 2 | Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer | May 2006 | July 2009 |
| NCT00268372 | Terminated | Phase 3 | S0427, Combination Chemotherapy & RT in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx | December 2005 | December 2007 |
| NCT00227617 | Terminated | Phase 2/Phase 3 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | June 8, 2005 | February 2016 |
| NCT01220128 | Terminated | Phase 2 | Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | April 11, 2011 | November 14, 2014 |
| NCT00209703 | Terminated | Phase 2 | Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer | January 2005 | June 2007 |
| NCT01324141 | Terminated | Phase 1 | Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer | March 18, 2011 | April 15, 2015 |
| NCT01372202 | Terminated | Phase 2 | CHFR Methylation Status Esophageal Cancer Study | June 2011 | October 1, 2014 |
| NCT01522612 | Terminated | Phase 2 | Colorectal Cancer (CRC) Cetuximab Elderly Frail | April 2013 | January 2015 |
| NCT01525329 | Terminated | Phase 3 | Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease | September 2011 | December 2016 |
| NCT00155883 | Terminated | Phase 2 | Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL) for Inoperable Advanced or Metastatic Gastric Cancer | June 2004 | July 2005 |
| NCT00065117 | Terminated | Phase 2 | Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer. | September 2003 | February 2004 |
| NCT01754623 | Terminated | Phase 2 | GTX-RT in Borderline Resectable Pancreatic Cancer | February 2013 | October 2014 |
| NCT01765582 | Terminated | Phase 2 | Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer | January 23, 2013 | March 14, 2016 |
| NCT01769508 | Terminated | Phase 2 | Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer | February 2013 | February 2015 |
| NCT00040391 | Terminated | Phase 2 | A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer | June 2002 | |
| NCT01985841 | Terminated | Phase 2 | Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer | October 2011 | April 2015 |
| NCT02099188 | Unknown status | Phase 2 | Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients | November 2013 | January 2024 |
| NCT01231802 | Unknown status | Phase 2 | Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer | April 2011 | January 2013 |
| NCT00499603 | Unknown status | Phase 2 | Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer | July 2007 | April 2017 |
| NCT01308086 | Unknown status | Phase 3 | Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer | October 2010 | December 2017 |
| NCT02376452 | Unknown status | Phase 2 | Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients | September 2014 | December 2016 |
| NCT01529164 | Unknown status | Phase 2 | Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer | October 2011 | September 2014 |
| NCT05229497 | Unknown status | Phase 1/Phase 2 | A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors | May 4, 2022 | February 2024 |
| NCT01716949 | Unknown status | Phase 1/Phase 2 | Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer | September 2012 | June 2023 |
| NCT02935764 | Unknown status | Phase 3 | FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients | October 2016 | |
| NCT02904031 | Unknown status | Phase 2 | Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients | July 2016 | October 2020 |
| NCT02785146 | Unknown status | Phase 3 | Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer | June 2016 | June 2018 |
| NCT02281682 | Unknown status | Phase 4 | IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis | November 2014 | December 2018 |
| NCT02099175 | Unknown status | Phase 2 | Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients | November 2013 | January 2024 |
| NCT03503604 | Unknown status | Phase 1 | A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors | May 1, 2018 | March 1, 2019 |
| NCT00943137 | Unknown status | Phase 2 | The Optimization of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer | June 2009 | June 2017 |
| NCT02523053 | Unknown status | N/A | Effect of Intraoperative Controlled Release 5-Fluorouracil Therapy on Recurrence in Hepatocellular Carcinoma Patients | April 2016 | December 2018 |
| NCT00563927 | Unknown status | N/A | Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0) | March 1999 | October 2009 |
| NCT03668730 | Unknown status | Phase 2 | Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma | October 19, 2018 | December 30, 2023 |
| NCT02485548 | Unknown status | Phase 3 | Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer | June 2015 | June 2018 |
| NCT01150045 | Unknown status | Phase 3 | Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery | June 2010 | |
| NCT00323583 | Unknown status | Phase 2 | Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer | May 2006 | |
| NCT03387592 | Unknown status | Phase 2 | CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas | March 6, 2017 | January 2022 |
| NCT01858025 | Unknown status | Early Phase 1 | Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma | July 2013 | December 2019 |
| NCT00577057 | Unknown status | N/A | Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer | September 2006 | August 2013 |
| NCT02369939 | Unknown status | Phase 3 | Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy | December 2014 | April 2021 |
| NCT04097444 | Unknown status | Phase 2 | CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC | October 11, 2019 | August 31, 2022 |
| NCT03219580 | Unknown status | Phase 3 | The Role of 5-Fluorouracil in Post-Operative Scar Formation Following Direct Brow Ptosis Repair | May 20, 2017 | August 1, 2020 |
| NCT01411072 | Unknown status | N/A | Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer | September 2011 | December 2015 |
| NCT04269369 | Unknown status | Phase 4 | Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients | February 18, 2020 | September 30, 2021 |
| NCT03210064 | Unknown status | Phase 2 | Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients | May 4, 2017 | April 24, 2019 |
| NCT05008887 | Unknown status | Phase 4 | Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo | September 2022 | April 2023 |
| NCT01327521 | Withdrawn | Phase 3 | Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma | February 2011 | |
| NCT04430985 | Withdrawn | Phase 2 | FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer | September 30, 2020 | September 6, 2021 |
| NCT00386516 | Withdrawn | Phase 2 | Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer | September 2006 | June 2009 |
| NCT03342352 | Withdrawn | Phase 3 | Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) | December 15, 2017 | April 20, 2018 |
| NCT03554109 | Withdrawn | Phase 2 | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | September 2018 | December 2021 |
| NCT03563144 | Withdrawn | Phase 2 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | August 2018 | December 30, 2019 |
| NCT01998347 | Withdrawn | Phase 3 | Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer | November 2013 | |
| NCT03307941 | Withdrawn | Phase 1/Phase 2 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA | July 20, 2017 | December 11, 2017 |
| NCT03197584 | Withdrawn | Phase 1/Phase 2 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | December 2017 | April 2019 |
| NCT01953406 | Withdrawn | Phase 2 | The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma | November 2015 | November 2015 |
| NCT03175666 | Withdrawn | Phase 1/Phase 2 | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy | December 2017 | March 2019 |
| NCT03563170 | Withdrawn | Phase 1/Phase 2 | QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | May 25, 2018 | August 23, 2019 |
| NCT05505539 | Withdrawn | Phase 1 | Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia | September 30, 2022 | December 31, 2023 |
| NCT03167177 | Withdrawn | Phase 1/Phase 2 | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT02345746 | Withdrawn | Phase 2 | Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis | December 2012 | December 2013 |
| NCT03167164 | Withdrawn | Phase 1/Phase 2 | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy | December 2017 | March 2019 |
| NCT04859582 | Withdrawn | Phase 3 | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension | November 8, 2018 | November 29, 2024 |
| NCT03037736 | Withdrawn | Phase 4 | Outpatient Performed Pterygium Surgery Study | March 1, 2020 | March 1, 2020 |